{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,6,9]],"date-time":"2026-06-09T12:10:31Z","timestamp":1781007031511,"version":"3.54.1"},"reference-count":35,"publisher":"SAGE Publications","issue":"3","license":[{"start":{"date-parts":[[2026,2,23]],"date-time":"2026-02-23T00:00:00Z","timestamp":1771804800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"},{"start":{"date-parts":[[2026,2,23]],"date-time":"2026-02-23T00:00:00Z","timestamp":1771804800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/journals.sagepub.com\/page\/policies\/text-and-data-mining-license"}],"funder":[{"DOI":"10.13039\/100000054","name":"National Cancer Institute","doi-asserted-by":"publisher","award":["R01CA152110"],"award-info":[{"award-number":["R01CA152110"]}],"id":[{"id":"10.13039\/100000054","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000054","name":"National Cancer Institute","doi-asserted-by":"publisher","award":["NIH 5 P30 CA06516"],"award-info":[{"award-number":["NIH 5 P30 CA06516"]}],"id":[{"id":"10.13039\/100000054","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["journals.sagepub.com"],"crossmark-restriction":true},"short-container-title":["Clinical Trials"],"published-print":{"date-parts":[[2026,6]]},"abstract":"<jats:sec>\n                    <jats:title>Background\/Aims:<\/jats:title>\n                    <jats:p>Clinical trials are commonly believed to benefit from the involvement of an academic principal investigator who accepts responsibility for design, conduct, and reporting. Little evidence exists, however, about the importance that diverse stakeholders assign to the principal investigator\u2019s role in leadership of trials. Furthermore, few studies have examined whether and how beliefs about the role of the principal investigator might vary by funding source.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods:<\/jats:title>\n                    <jats:p>We conducted parallel Delphi panel surveys with seven stakeholder groups (principal investigators, patient advocates, journal editors, public funders, industry representatives, United States Food and Drug Administration officials, and clinical trial cooperative-group chairs) to assess the extent to which respondents believed leadership of a multicenter randomized controlled trial by an academic principal investigator to be important, considering publicly and industry-funded trials separately. We then surveyed an international sample of principal investigators (N\u2009=\u200992) who had recently published a multicenter randomized controlled trial in a high-impact general medical, oncology, cardiovascular, or psychiatry journal to assess their normative views on the importance of the academic principal investigator in leading both publicly and industry-funded trials.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results:<\/jats:title>\n                    <jats:p>Several patterns emerged from the Delphi panel surveys. First, panelists viewed involvement of an identified academic principal investigator as most important at the design and planning and the interpretation and dissemination phases of a trial, as compared with the implementation and data collection phase. Second, panelists generally viewed involvement of an identified academic principal investigator as more important in publicly funded than in industry-funded trials. Finally, panelists representing industry stakeholders and United States Food and Drug Administration officials viewed involvement of an identified academic principal investigator as less important, especially for industry-funded trials, than did other groups. Respondents to the normative principal investigator survey generally endorsed the importance of academic principal investigators in leading multicenter randomized controlled trials, both overall (median rating 6 on the 0\u20136 point scale) and for trial-specific tasks. Both overall and with respect to specific tasks, however, respondents viewed an academic principal investigator\u2019s leadership as more important when considering publicly funded as compared with industry-funded trials.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusion:<\/jats:title>\n                    <jats:p>Although members of most stakeholder groups participating in Delphi surveys view involvement of an academic principal investigator with overall responsibility for a multicenter randomized controlled trial as very important, there are notable differences depending on the respondent\u2019s perspective, the specific trial-related task, and the source of funding for the trial. In addition, principal investigators generally view an academic principal investigator as more important to the validity of a publicly funded multicenter randomized controlled trial than to the that of an industry-funded trial. These findings highlight the need to clarify the real-world practices of clinical trial leadership across diverse settings and to assess how those practices align with widely shared norms.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1177\/17407745261417337","type":"journal-article","created":{"date-parts":[[2026,2,24]],"date-time":"2026-02-24T06:48:01Z","timestamp":1771915681000},"page":"325-335","update-policy":"https:\/\/doi.org\/10.1177\/sage-journals-update-policy","source":"Crossref","is-referenced-by-count":0,"title":["Stakeholder views about the responsibilities of principal investigators in multicenter randomized controlled trials"],"prefix":"10.1177","volume":"23","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-0667-7384","authenticated-orcid":false,"given":"Steven","family":"Joffe","sequence":"first","affiliation":[{"name":"Department of Medical Ethics &amp; Health Policy, Perelman School of Medicine at the University of Pennsylvania, Philadelphia, PA, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-0389-4022","authenticated-orcid":false,"given":"Elizabeth F","family":"Bair","sequence":"additional","affiliation":[{"name":"Department of Medical Ethics &amp; Health Policy, Perelman School of Medicine at the University of Pennsylvania, Philadelphia, PA, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-2609-2690","authenticated-orcid":false,"given":"Katharine A","family":"Gleason","sequence":"additional","affiliation":[{"name":"Department of Medical Ethics &amp; Health Policy, Perelman School of Medicine at the University of Pennsylvania, Philadelphia, PA, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-3265-217X","authenticated-orcid":false,"given":"Deborah E","family":"Sellers","sequence":"additional","affiliation":[{"name":"Bronfenbrenner Center for Translational Research, Cornell University, Ithaca, NY, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-3208-8129","authenticated-orcid":false,"given":"Sarah A","family":"McGraw","sequence":"additional","affiliation":[{"name":"The Hastings Center for Bioethics, Garrison, NY, USA"},{"name":"MNW Consulting Group, LLC. Portland, OR, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-4974-935X","authenticated-orcid":false,"given":"Cary P","family":"Gross","sequence":"additional","affiliation":[{"name":"Department of Medicine and Cancer Outcomes, Yale School of Medicine, New Haven, CT, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-1081-1053","authenticated-orcid":false,"given":"Donna T","family":"Chen","sequence":"additional","affiliation":[{"name":"Center for Health Humanities &amp; Ethics, University of Virginia School of Medicine, Charlottesville, VA, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0002-2777-1246","authenticated-orcid":false,"given":"Eric G","family":"Campbell","sequence":"additional","affiliation":[{"name":"Center for Bioethics and Humanities, University of Colorado Anschutz Medical Campus, Aurora, CO, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-2877-4270","authenticated-orcid":false,"given":"Michelle M","family":"Mello","sequence":"additional","affiliation":[{"name":"Department of Health Policy, Stanford University School of Medicine, Stanford, CA, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"179","published-online":{"date-parts":[[2026,2,23]]},"reference":[{"key":"e_1_3_3_2_2","doi-asserted-by":"publisher","DOI":"10.1001\/jama.289.4.454"},{"key":"e_1_3_3_3_2","doi-asserted-by":"publisher","DOI":"10.1001\/jama.290.7.921"},{"key":"e_1_3_3_4_2","doi-asserted-by":"publisher","DOI":"10.1001\/jama.295.19.2270"},{"key":"e_1_3_3_5_2","doi-asserted-by":"publisher","DOI":"10.1136\/bmj.326.7400.1167"},{"key":"e_1_3_3_6_2","doi-asserted-by":"publisher","DOI":"10.1136\/bmj.325.7358.249"},{"issue":"4","key":"e_1_3_3_7_2","first-page":"477","article-title":"Association between industry funding and statistically significant pro-industry findings in medical and surgical randomized trials","volume":"170","author":"Bhandari M","year":"2004","unstructured":"Bhandari M, Busse JW, Jackowski D, et al. Association between industry funding and statistically significant pro-industry findings in medical and surgical randomized trials. CMAJ 2004; 170(4): 477\u2013480.","journal-title":"CMAJ"},{"key":"e_1_3_3_8_2","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMsa0906126"},{"key":"e_1_3_3_9_2","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pmed.1001378"},{"key":"e_1_3_3_10_2","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMe058314"},{"key":"e_1_3_3_11_2","doi-asserted-by":"publisher","DOI":"10.1001\/jama.296.8.jed60051"},{"key":"e_1_3_3_12_2","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pmed.1000156"},{"key":"e_1_3_3_13_2","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pmed.1000230"},{"key":"e_1_3_3_14_2","doi-asserted-by":"publisher","DOI":"10.1001\/jama.299.15.1800"},{"key":"e_1_3_3_15_2","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pmed.0040019"},{"key":"e_1_3_3_16_2","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMsa1202397"},{"key":"e_1_3_3_17_2","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMsr1414226"},{"key":"e_1_3_3_18_2","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMed20010093"},{"key":"e_1_3_3_19_2","doi-asserted-by":"publisher","DOI":"10.1001\/jama.294.1.110"},{"key":"e_1_3_3_20_2","doi-asserted-by":"publisher","DOI":"10.1136\/bmj.323.7313.588"},{"key":"e_1_3_3_21_2","doi-asserted-by":"publisher","DOI":"10.1001\/jama.1997.03550070071041"},{"key":"e_1_3_3_22_2","unstructured":"International Committee of Medical Journal Editors. Defining the role of authors and contributors http:\/\/www.icmje.org\/recommendations\/browse\/roles-and-responsibilities\/defining-the-role-of-authors-and-contributors.html (accessed 11 November 2025)."},{"key":"e_1_3_3_23_2","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2009.26.9753"},{"key":"e_1_3_3_24_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.ejca.2005.07.010"},{"key":"e_1_3_3_25_2","unstructured":"National Center for Advancing Translational Sciences. Toolkit for patient-focused therapy development https:\/\/toolkit.ncats.nih.gov\/glossary\/principal-investigator\/ (accessed 11 November 2025)."},{"key":"e_1_3_3_26_2","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMsa044115"},{"key":"e_1_3_3_27_2","volume-title":"The Delphi method: techniques and applications","author":"Linstone HA","year":"2002","unstructured":"Linstone HA, Turoff M. The Delphi method: techniques and applications. Reading, MA: Addison-Wesley, 2002."},{"key":"e_1_3_3_28_2","volume-title":"The RAND\/UCLA appropriateness method user\u2019s manual","author":"Fitch K","year":"2001","unstructured":"Fitch K, Bernstein SJ, Aguilar MS, et al. The RAND\/UCLA appropriateness method user\u2019s manual. Santa Monica, CA: RAND Corporation, 2001."},{"key":"e_1_3_3_29_2","volume-title":"Clinical trials: a practical approach","author":"Pocock SJ.","year":"1983","unstructured":"Pocock SJ. Clinical trials: a practical approach. New York: Wiley, 1983."},{"key":"e_1_3_3_30_2","unstructured":"United States Food | Drug Administration. Guidance for industry. Investigator responsibilities\u2014protecting the rights safety and welfare of study subjects https:\/\/www.fda.gov\/media\/77765\/download (2009 accessed 11 November 2025)."},{"key":"e_1_3_3_31_2","doi-asserted-by":"publisher","DOI":"10.31486\/toj.19.0085"},{"key":"e_1_3_3_32_2","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0001610"},{"key":"e_1_3_3_33_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.techfore.2011.07.007"},{"issue":"183","key":"e_1_3_3_34_2","first-page":"65138","article-title":"Final rule: clinical trials registration and results information submission. 42 CFR Part 11","volume":"81","author":"National Institutes of Health, Department of Health and Human Services","year":"2016","unstructured":"National Institutes of Health, Department of Health and Human Services. Final rule: clinical trials registration and results information submission. 42 CFR Part 11. Fed Regist 2016; 81(183): 65138.","journal-title":"Fed Regist"},{"key":"e_1_3_3_35_2","unstructured":"Secretary\u2019s Advisory Committee on Human Research Protections. Attachment C: investigator responsibilities; January 10 2013 SACHRP letter to the HHS Secretary https:\/\/www.hhs.Gov\/ohrp\/sachrp-committee\/recommendations\/2013-january-10-letter-attachment-c\/index.html (2013 accessed 11 November 2025)."},{"key":"e_1_3_3_36_2","unstructured":"Presidential Commission for the Study of Bioethical Issues. Moral science: protecting participants in human subject\u2019s research https:\/\/bioethicsarchive.georgetown.edu\/pcsbi\/sites\/default\/files\/Moral%20Science%20June%202012.pdf (2011 accessed 11 November 2025)."}],"container-title":["Clinical Trials"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/journals.sagepub.com\/doi\/pdf\/10.1177\/17407745261417337","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/journals.sagepub.com\/doi\/full-xml\/10.1177\/17407745261417337","content-type":"application\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/journals.sagepub.com\/doi\/pdf\/10.1177\/17407745261417337","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,6,9]],"date-time":"2026-06-09T11:56:39Z","timestamp":1781006199000},"score":1,"resource":{"primary":{"URL":"https:\/\/journals.sagepub.com\/doi\/10.1177\/17407745261417337"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,2,23]]},"references-count":35,"journal-issue":{"issue":"3","published-print":{"date-parts":[[2026,6]]}},"alternative-id":["10.1177\/17407745261417337"],"URL":"https:\/\/doi.org\/10.1177\/17407745261417337","relation":{},"ISSN":["1740-7745","1740-7753"],"issn-type":[{"value":"1740-7745","type":"print"},{"value":"1740-7753","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,2,23]]}}}